The evidence that GLP-1 drugs can protect from cognitive decline keeps rolling out. Now, we have a meta-analysis of trials showing that these drugs provide clinically meaningful improvements in the rate of cognitive decline compared to placebo or other, conventional treatment.

The threshold for MMSE-based clinical significance is generally thought to be about a 1-3-point decline over 1 year, and this saw a >1-point improvement in ~24 weeks. Harder to judge the MoCA result because there are four common, discrepant thresholds for clinical significance.

But this result clears 2/4 of those (1.6-point, 1-point), and ~maybe clears the third (2-point), and it does so in a fraction of the time (one year) associated with those changes. So yes, it seems GLP-1RAs deliver clinically-meaningful protection against cognitive decline!